- Home
- AL vs TGTX Comparison
AL vs TGTX Comparison
Compare AL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AL
- TGTX
- Stock Information
- Founded
- AL 2010
- TGTX 1993
- Country
- AL United States
- TGTX United States
- Employees
- AL N/A
- TGTX N/A
- Industry
- AL Diversified Commercial Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- AL Consumer Discretionary
- TGTX Health Care
- Exchange
- AL Nasdaq
- TGTX Nasdaq
- Market Cap
- AL 5.4B
- TGTX 5.4B
- IPO Year
- AL 2011
- TGTX 1995
- Fundamental
- Price
- AL $48.59
- TGTX $32.20
- Analyst Decision
- AL Strong Buy
- TGTX Strong Buy
- Analyst Count
- AL 5
- TGTX 6
- Target Price
- AL $57.20
- TGTX $40.67
- AVG Volume (30 Days)
- AL 678.3K
- TGTX 2.2M
- Earning Date
- AL 02-13-2025
- TGTX 11-04-2024
- Dividend Yield
- AL 1.75%
- TGTX N/A
- EPS Growth
- AL N/A
- TGTX N/A
- EPS
- AL 4.39
- TGTX N/A
- Revenue
- AL $2,737,330,000.00
- TGTX $264,790,000.00
- Revenue This Year
- AL $3.69
- TGTX $43.74
- Revenue Next Year
- AL $12.32
- TGTX $64.30
- P/E Ratio
- AL $11.07
- TGTX N/A
- Revenue Growth
- AL 6.51
- TGTX 39.53
- 52 Week Low
- AL $39.15
- TGTX $12.84
- 52 Week High
- AL $52.31
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- AL 48.06
- TGTX 51.73
- Support Level
- AL $46.72
- TGTX $30.41
- Resistance Level
- AL $49.99
- TGTX $35.03
- Average True Range (ATR)
- AL 1.30
- TGTX 1.80
- MACD
- AL -0.46
- TGTX -0.46
- Stochastic Oscillator
- AL 37.78
- TGTX 35.31
About AL Air Lease Corporation
Air Lease Corp is an aircraft leasing company based in the United States. However, it derives its revenue from the Asia region. Its business involves purchasing aircraft from renowned manufacturers such as The Boeing Company (Boeing) and Airbus S.A.S and leasing them to airline companies across the world. Its suite of aircraft entails single-aisle narrow-bodied jets and twin-aisle wide-bodied aircraft. The company earns from revenue originates from the renting of flight equipment. Geographically it operates in Asia Pacific, Europe, The Middle East and Africa, Central America, South America and Mexico and U.S. and Canada.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.